Miltenyi Biotec, Inc.

Miltenyi Biotec, Inc., a foreign-owned, for-profit manufacturer headquartered in Auburn, California, supplies specialized cell separation, analysis, and processing instruments and proprietary consumables to the federal research and clinical-translation ecosystem as a prime contractor. The vendor competes full-and-open without set-aside posture across all award types. Miltenyi Biotec's concrete capability footprint centers on GentleMACS Octo Dissociators (automated tissue dissociation instruments), MACSQuant flow cytometers and cell sorters, CliniMACS automated cell isolation systems, and CliniMACS cell isolation reagents and consumables—all proprietary products for which Miltenyi is frequently the sole available source under simplified acquisition procedures. Representative work spans a $5.8 million single-award indefinite delivery contract with the NIH Clinical Center (awarded June 26, 2023, running through September 2026) for CliniMACS cell isolation reagents and consumables supporting Good Manufacturing Practice-compliant production of investigational cell therapy products across 50-plus intramural clinical trials; a $749.2 million purchase order from the Food and Drug Administration (awarded August 8, 2023) for a MACSima imaging system through March 31, 2029; a $450.9 thousand purchase order from the National Institute of Allergy and Infectious Diseases (awarded September 26, 2024) for a MACSima platform including imaging system, starter kit, installation, training, and software license; and a $275.2 thousand purchase order from the USDA Agricultural Research Service (awarded September 18, 2025) for a MACSQuant Tyto Cell Sorter supporting research at the National Poultry Research Center. All awards are firm fixed-price, non-competitive procurements reflecting the vendor's position as a specialized sole-source supplier.

Customer concentration is heavily skewed toward National Institutes of Health institutes. The top five funding customers by award count—National Cancer Institute (130 awards, $2.9 million), NIAID Acquisitions (106 awards, $1.2 million), NIH Office of the Director (104 awards, $907 thousand), NIAID proper (102 awards, $3.8 million), and NIH Clinical Center (86 awards, $23.7 million)—account for 39% of recent awards. By dollars, however, the NIH Clinical Center anchors the customer base at $23.7 million of $62.3 million combined potential value across 1,361 prime awards, reflecting the vendor's deep embedded position in the Clinical Center's cell therapy manufacturing operations. The NIH Clinical Center's 86 awards represent the single-largest customer relationship by both volume and value. FDA, with 37 awards and $2.3 million combined potential value, represents the second-largest dollar customer outside NIH. The top two parent vehicles are an indefinite delivery contract (HHSN269201700011I) with 6 task orders worth $7.3 million and a blanket purchase agreement (W81XWH17A0017) with 5 task orders worth $69 thousand. Most awards are standalone purchase orders tied to no named parent vehicle.

Activity has declined in recent years. The vendor recorded 44 awards in 2022, 57 in 2023, 34 in 2024, 13 in 2025, and 7 through mid-2026—a sustained downward trend. Combined potential value across all 1,361 awards (dating to 2000) totals $62.3 million, with $52.5 million (84%) obligated. Thirteen awards with ultimate completion dates in the next 24 months carry combined potential value of $2.5 million, exposing the vendor to moderate recompete pressure. The vendor's award footprint is concentrated in laboratory equipment and supplies (654 awards), maintenance and repair of laboratory instruments (249 awards), drugs and biologicals (97 awards), and medical and surgical instruments (94 awards), reflecting its primary NAICS categories of analytical laboratory instrument manufacturing (435 awards), in-vitro diagnostic substance manufacturing (111 awards), and equipment repair and maintenance (113 awards).

Miltenyi Biotec holds a single sub-award: a June 20, 2024, sub-contract under Illumina, Inc. for COVID-19 serology testing services and cell and gene therapy applications. The vendor operates as a prime on 1,360 of 1,361 awards (99.9% prime posture). The vendor serves 68 distinct customer agencies, with heavy concentration in HHS, VA, USDA, DoD, and CDC.